Go Deep
Beta Drugs Limited
Beta Drugs Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,748 | 25.3 | 7.12 | 0.60 | 1,719.60 |
Beta Drugs Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,255,495,637.6 | 939,649,419.4 | 872,675,344.7 | 1,033,864,143.1 |
| Net Profit | 158,018,248.3 | 90,489,234.0 | 85,172,567.3 | 122,179,453.8 |
| EPS | 14.8 | 8.9 | 8.4 | — |
Beta Drugs Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 3,848,258,000.0 | 3,623,557,000.0 | 2,957,137,593.9 | 2,271,136,000.0 | — |
| Net Profit | 414,827,000.0 | 424,186,000.0 | 364,370,111.6 | 307,187,000.0 | — |
| EPS | 40.9 | 42.0 | 37.9 | 30.4 | — |
Beta Drugs Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 4,957,996,000.0 | 4,362,347,000.0 | 2,540,986,077.8 | 1,984,215,000.0 | — |
| Total Liabilities | 2,510,291,000.0 | 2,391,389,000.0 | 969,816,963.5 | 755,373,000.0 | — |
| Total Equity | 2,447,705,000.0 | 1,970,958,000.0 | 1,571,169,114.2 | 1,228,842,000.0 | — |
Owes vs Owns
Beta Drugs Limited owed ₹0.51 for every ₹1 it owned in Mar 2026, up from ₹0.38 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.51× | 0.55× | 0.38× | 0.38× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Beta Drugs Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 25.2%Receivables 24.0%Inventory 15.0%Fixed assets (tangible) 25.4%Intangible assets 2.0%Other assets 8.4%
How it's funded — Mar 2026
Short-term debt 2.9%Long-term debt 26.9%Payables 16.3%Other liabilities 4.6%Shareholders' equity 49.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 124.8 | 147.0 | 28.6 | 19.2 |
| Receivables | 119.1 | 102.6 | 79.2 | 62.7 |
| Inventory | 74.5 | 59.8 | 49.8 | 30.6 |
| Fixed assets (tangible) | 125.9 | 91.3 | 67.0 | 62.1 |
| Intangible assets | 9.9 | 8.6 | 5.4 | 4.7 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.8 |
| Other assets | 41.5 | 27.0 | 24.0 | 18.4 |
| Liabilities & equity | ||||
| Short-term debt | 14.5 | 11.1 | 8.7 | 13.4 |
| Long-term debt | 133.3 | 127.0 | 6.0 | 7.0 |
| Payables | 80.6 | 71.3 | 59.3 | 40.2 |
| Other liabilities | 22.6 | 29.8 | 23.0 | 15.0 |
| Shareholders' equity | 244.8 | 197.1 | 157.1 | 122.9 |
| Net tangible assets | 234.9 | 188.5 | 151.7 | 118.2 |
Beta Drugs Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 372,861,000.0 | 361,442,000.0 | 309,302,994.2 | 233,825,000.0 | — |
| Investing Activities | -513,907,000.0 | -357,182,000.0 | -139,718,865.5 | -190,689,000.0 | — |
| Financing Activities | -80,713,000.0 | 1,179,654,000.0 | -74,898,545.3 | -24,736,000.0 | — |